MA-WASABI-TECHNOLOGIES
9.5.2023 09:01:29 CEST | Business Wire | Press release
Wasabi Technologies, the hot cloud storage company, strengthened its foothold in EMEA with the appointment of Jon Howes as Vice President and General Manager for EMEA. Howes will build on Wasabi’s momentous growth in the region, highlighted by a flagship deal with Liverpool Football Club, 1,800 new partners, and a nearly 90% ARR growth rate. Additionally, a full region go-to-market team has been established to support the growth of cloud storage, with Eric Peters as Country Manager of Benelux & Southern Europe based in France; Daniel Arabié, Country Manager of Central Europe/DACH based in Germany, and Kevin Dunn, Country Manager for the UK/I & Nordics based in the UK.
Jon Howes, VP and GM for EMEA, Wasabi Technologies, said:
“Demand for predictably priced, secure, high-performance cloud storage is growing at an unprecedented pace in EMEA, making Wasabi a perfect fit for the market. Our immense traction across Europe is a testament to the value we bring to enterprises and organisations across sports, media and entertainment, surveillance, education, healthcare, and more. Being at the helm of Wasabi’s EMEA operations is a once-in-a-lifetime opportunity, and I look forward to the expansion of Wasabi hot cloud storage in this important region along with our industry-leading team.”
Howes brings more than 20 years’ experience to Wasabi, with deep expertise in scaling go-to-market models for technology companies in EMEA including Juniper Networks, Oracle and Infovista. His initial priorities will be growing Wasabi’s channel presence, scaling its partner and customer base, and strategically increasing Wasabi’s headcount in key European markets, specifically the UK, France and Germany. Meanwhile, Wasabi’s newly appointed country managers hold a plethora of proven sales and channel experience with organisations including AWS, Cloudian, EMC, Juniper Networks, Nimble Storage, and others.
Wasabi’s 'channel-first’ approach in EMEA has established partnerships with Exclusive Networks, Ebertlang, Veeam, Equinix, and more – most recently Skill Partner. Marquee customer wins include Liverpool Football Club, who migrated to Wasabi for predictable, affordable cloud storage without fees for egress or API requests in order to create a central repository for all the club’s digital media.
Drew Crisp, SVP of Digital at Liverpool Football Club, said:
“Many cloud vendors try to be all things to all people, to the customer’s detriment. Wasabi’s singular focus on cloud storage has made them brilliant at what they do. They know the cloud storage space inside and out and have worked with us every step of the way. Not only does Liverpool FC have a very simple cost model with Wasabi as we migrate from on-premises to the cloud, we have price predictability that enables us to truly understand our total cost of ownership, which is essential for us.”
Arnaud Semont, Associate Director at Skill Partner, said:
“Skill Partner goes to market with innovative, disruptive and predictable IT solutions, which is why we partner with Wasabi on our backup and disaster recovery services. We use Wasabi cloud storage to keep an external copy of our customers' data using immutable storage, which ensures data is safe from ransomware with object lock. As a system integrator and service provider based in EMEA, Wasabi's local storage regions help us meet data sovereignty requirements, allowing us to use the Wasabi Paris storage region with replication to Frankfurt.”
Wasabi hot cloud storage is the industry’s most reliable, scalable, and predictably priced cloud storage with no fees for egress or API requests and no vendor lock-in. Wasabi is gaining market traction at a phenomenal pace as organisations globally are looking for cloud storage solutions that fit their budgets and unique needs. It’s also an ideal product for the channel because every organisation needs to store data and Wasabi is simple to understand and integrate with other best-of-breed products. It also offers the highest level of protection in cloud storage with Object Lock immutability and 11 x 9s of data durability. Service launched in EMEA in 2019 with the opening of the Amsterdam storage region. Since then, Wasabi has added storage regions in London, Frankfurt, and Paris to support the company’s rapid growth and to meet customer data sovereignty needs.
Companies in every industry can benefit from Wasabi hot cloud storage and its suite of supporting products and tools like the recently announced Wasabi Surveillance Cloud, which delivers bottomless storage for video surveillance, and a state-of-the-art Carbon Footprint Calculator that helps customers and partners accurately measure and report on their energy use in specific Wasabi data centres as part of their broader ESG objectives.
Regularly named one of technology’s fastest-growing companies, and recognized by analysts as the top alternative to AWS S3, Wasabi has raised over $500 million in funding to support its international expansion and availability for customers of every size. For more information on how Wasabi can partner with your organisation, visit here or contact emeasales@wasabi.com.
About Wasabi Technologies
Wasabi provides simple and affordable hot cloud storage for businesses all over the world. It enables organisations to store and instantly access an unlimited amount of data with no complex tiers or egress or API fees, delivering predictable costs that save money and industry leading security and performance businesses can count on. Trusted by customers worldwide, Wasabi has been recognized as one of technology’s fastest-growing and most visionary companies. Created by Carbonite co-founders and cloud storage pioneers David Friend and Jeff Flowers, Wasabi is a privately held company based in Boston. Wasabi is a Proud Partner of the Boston Red Sox, and the Official Cloud Storage Partner of Liverpool Football Club and the Boston Bruins.
Follow and connect with Wasabi on Linkedin,Twitter, Facebook, Instagram, and The Bucket.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005191/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom